Breaking News Headlines Today | Ground News

See every side of every news story

biopharmadive.com image

News from biopharmadive.com

The Ground News media bias check for biopharmadive.com is Center. Scores are assigned by aggregating bias scores from Ad Fontes Media, Media Bias/Fact Check, and AllSides.

biopharmadive.com’s aggregated factuality score is High. Factuality is assigned by combining fact check, credibility, and reliability ratings from Ad Fontes Media and Media Bias/Fact Check.

Information about biopharmadive.com

Where is biopharmadive.com located?biopharmadive.com's Website

Media Bias Ratings

Average Bias Rating:

Center

Center

byMedia Bias/Fact Check

Do you disagree?

Edit bias

Learn more about Media Bias Ratings.

Factuality

Learn more about Factuality Ratings

Reveal Factuality Ratings by upgrading to a Premium account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Ownership

Learn more about Ownership categories

Reveal Ownership Data by upgrading to a Vantage account.

Tap Upgrade to explore subscription options to meet all your reading needs.

Top biopharmadive.com News

Trump administration announces 15 new drugs for Medicare price negotiation program — REUTERS / Kevin Lamarque

Medicare · United States

Trump administration announces 15 new drugs for Medicare price negotiation program

77% Center coverage: 78 sources

Drugs that treat Type 2 diabetes, HIV and arthritis are among 15 new medications chosen for a Medicare drug price negotiation program that allows the federal government to haggle directly with drug manufacturers, the Trump administration said Tuesday.See the Story

Lilly bets on Seamless, delving further into genetic medicine for hearing loss

Biotech · Dresden

Lilly bets on Seamless, delving further into genetic medicine for hearing loss

67% Center coverage: 3 sources

The potentially $1 billion alliance centered around a flexible gene editing technology adds to a portfolio of cutting-edge treatments the company is developing for hearing disorders.See the Story

Regenxbio Gene Therapy Trials Suspended by FDA over Safety Worries

United States · United States

Regenxbio Gene Therapy Trials Suspended by FDA over Safety Worries

100% Center coverage: 2 sources

The development of a brain tumor in a study participant led regulators to suspend a Hurler syndrome therapy in early testing and a treatment for Hunter syndrome nearing an FDA decision.See the Story

Breaking News Topics Related to biopharmadive.com